| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment | 5 | Benzinga.com | ||
| Mo | Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations | 8 | FierceBiotech | ||
| Mo | Merck discontinues testing of experimental skin cancer combo therapy | 2 | Seeking Alpha | ||
| Mo | Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma | 314 | AFX News | KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK) announced Monday the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial in patients... ► Artikel lesen | |
| Mo | Merck stops skin cancer combination therapy testing in late-stage study | 7 | Reuters | ||
| Do | Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer | 6 | FiercePharma | ||
| Do | Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal | 323 | AFX News | KENILWORTH (NJ) (dpa-AFX) - Drug major Merck & Co., Inc. (MRK) announced Thursday that the Phase 3 KEYNOTE-B21 trial evaluating its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination... ► Artikel lesen | |
| Do | Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults | 187 | AFX News | KENILWORTH (NJ) (dpa-AFX) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally... ► Artikel lesen | |
| Do | Merck's endometrial cancer therapy fails trial | 6 | Reuters | ||
| Do | Merck says Keytruda failed as first-line therapy for uterine cancer | 6 | Seeking Alpha | ||
| Mi | Merck & Co., Inc.: Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers | 270 | ACCESSWIRE | Surpasses its goal of reaching 25 million women by 2025RAHWAY, NJ / ACCESSWIRE / May 8, 2024 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Merck for... ► Artikel lesen | |
| 07.05. | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab) | 139 | GlobeNewswire (Europe) | - CX-801 is a dually masked, conditionally activated IFNa2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in... ► Artikel lesen | |
| 06.05. | Dow Jones Drug Giant Merck, Nvidia Eye Buy Points In Current Stock Market | 20 | Investor's Business Daily | ||
| 06.05. | Gossamer sells rights to drug it hopes can rival a new Merck therapy | 5 | BioPharma Dive | ||
| 06.05. | Biocartis Expands Partnership With Merck In Middle East And North Africa | 364 | AFX News | BERLIN (dpa-AFX) - Biocartis, a molecular diagnostics company, Monday announced expansion of its partnership with Merck KGaA (MKGAY.PK) in the Middle East and North Africa (MEA) region to improve... ► Artikel lesen | |
| 03.05. | Merck & Co., Inc. - 10-Q, Quarterly Report | 10 | SEC Filings | ||
| 03.05. | As rival Merck monopolizes BCG supply, ImmunityBio taps Serum Institute for new combo's manufacturing | 26 | FiercePharma | ||
| 02.05. | Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration | 14 | Benzinga.com | ||
| 02.05. | Cerevance receives milestone payment under Alzheimer's collaboration with Merck | 5 | Seeking Alpha | ||
| 01.05. | Research and Markets: Europe DNA/RNA Sample Extraction and Isolation Market Analysis Report 2023-2033 Featuring F. Hoffmann-La Roche, MACHEREY-NAGEL, Merck, QIAGEN, & Tecan Group - ResearchAndMarkets.com | 547 | Business Wire | The "Europe DNA/RNA Sample Extraction and Isolation Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe DNA/RNA sample extraction and... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.809 |
| TUI | 1.916 |
| BAYER | 1.714 |
| NEL | 1.702 |
| PLUG POWER | 1.546 |
| GAMESTOP | 1.282 |
| SIEMENS ENERGY | 1.201 |
| NVIDIA | 1.077 |
| RHEINMETALL | 1.058 |
| NOVAVAX | 1.051 |
| MERCEDES-BENZ | 969 |
| DEUTSCHE BANK | 812 |
| BYD | 735 |
| TESLA | 723 |
| PALANTIR TECHNOLOGIES | 703 |
| ALIBABA | 700 |
| VOLKSWAGEN | 670 |
| AMC ENTERTAINMENT | 660 |
| ALLIANZ | 633 |
| RWE | 633 |
| AIXTRON SE | 629 |
| NORDEX | 613 |
| K+S | 585 |
| COMMERZBANK | 573 |
| DEUTSCHE LUFTHANSA | 541 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
